Navigation Links
Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Date:1/3/2013

Seattle, Washington (PRWEB) January 03, 2013

Biosim Pharmaceuticals LLC (http://www.biosimllc.com) today announced it will be participating in the Biotech Showcase 2013 on January 7th-9th. The Biotech showcase, held alongside the JP Morgan 2013 Healthcare Conference in San Francisco, brings together biopharmaceutical executives from around the world into a collaborative learning environment.

Biosim Pharmaceuticals, LLC will be scheduling private one to one meetings with partners and interested companies throughout the conference regarding Biosim's flagship product, a generic ACTHAR gel. The brand H.P. ACTHAR gel is a highly purified corticotrophin gelatin depot formulation manufactured by Questcor Pharmaceuticals for the treatment of infantile spasms, multiple sclerosis, nephrotic syndrome and rheumatic disorders. Please contact bd(at)biosimllc(dot)com to schedule a meeting.

About BioSim Pharmaceuticals:
BioSim (biosimllc.com), a Seattle-based pharmaceutical company, focuses on building a portfolio of generic drugs for the orphan disease markets. BioSim consists of a team of highly capable individuals working together to implement both the near, and long-term objectives of advancing our pre-clinical and clinical development, all the way through late-stage development.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10286464.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
2. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
3. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
4. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
5. Biosimilars: Global Markets
6. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Charm Sciences, Inc. is pleased ... (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... Sciences to monitor aflatoxin in grains utilizing Charm’s ... FAST Aflatoxin Quantitative Test (solvent-based). , The Charm ... Water Extraction Technology to extract aflatoxin from the ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... , , ATLANTA, Sept. ... Board: EAUI), a leading provider of electrolyzed water for high-volume, ... trial with a leading international beverage bottling company enabling the ... sanitation process for CIP (Clean-in-Place) applications. EAU,s electrolyzed water ...
... , ... Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities. ... Basel, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, ...
... , , , CLEVELAND, ... GanedenBC30(R) , today announced the launch of the first ... the latest in a number of innovative probiotic-enhanced products introduced by Ganeden ... recent popularity of thin strips as a supplement delivery system led Ganeden ...
Cached Biology Technology:EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 3EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 4Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 2Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 3Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 4Ganeden Biotech Introduces the First Probiotic Thin Strip 2Ganeden Biotech Introduces the First Probiotic Thin Strip 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant mouse ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
E1A (adenovirus early region 1)...
Biology Products: